Johnson & Johnson Beats Q1 Estimates on Darzalex, Tremfya and Erleada
Johnson & Johnson beat first-quarter earnings and sales estimates as its Innovative Medicines unit saw stronger-than-expected performance from Darzalex, Tremfya and Erleada despite Stelara’s loss of exclusivity. Its Carvykti CAR-T therapy for multiple myeloma generated $1.89 billion in 2025, reinforcing J&J’s leadership in that treatment segment.
1. Q1 Beat Driven by Key Drugs
Johnson & Johnson’s first-quarter results surpassed analyst forecasts, led by its Innovative Medicines unit where Darzalex, Tremfya and Erleada each posted sales above expectations. This outperformance offset revenue declines from Stelara following its loss of exclusivity, helping the company deliver an overall earnings and sales beat.
2. Carvykti Maintains CAR-T Leadership
The company’s CAR-T therapy Carvykti generated $1.89 billion in sales in 2025, underscoring J&J’s dominant position in multiple myeloma treatments. Strong uptake and expanding indications have kept Carvykti ahead of competing therapies in the rapidly growing gene-based oncology market.